Insider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Sells $17,284.96 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Benjamin Jackson sold 7,084 shares of Sera Prognostics stock in a transaction dated Thursday, May 8th. The shares were sold at an average price of $2.44, for a total value of $17,284.96. Following the completion of the sale, the general counsel now owns 131,460 shares of the company’s stock, valued at $320,762.40. This trade represents a 5.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Benjamin Jackson also recently made the following trade(s):

• On Thursday, March 6th, Benjamin Jackson sold 2,285 shares of Sera Prognostics stock. The stock was sold at an average price of $4.16, for a total value of $9,505.60.

Sera Prognostics Stock Performance

Shares of NASDAQ:SERA opened at $2.22 on Monday. Sera Prognostics, Inc. has a 1 year low of $2.10 and a 1 year high of $9.91. The stock has a market capitalization of $83.61 million, a P/E ratio of -2.24 and a beta of 0.99. The stock has a 50-day simple moving average of $3.48 and a 200-day simple moving average of $5.49.

Sera Prognostics (NASDAQ:SERA) last issued its earnings results on Wednesday, May 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.06 million. Analysts predict that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Institutional Trading of Sera Prognostics

Institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. grew its holdings in shares of Sera Prognostics by 7,357.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 884,867 shares of the company’s stock worth $6,902,000 after purchasing an additional 873,002 shares during the period. Sanders Morris Harris LLC lifted its position in Sera Prognostics by 165.7% during the 4th quarter. Sanders Morris Harris LLC now owns 90,600 shares of the company’s stock worth $725,000 after acquiring an additional 56,500 shares in the last quarter. Barclays PLC lifted its position in Sera Prognostics by 321.6% during the 3rd quarter. Barclays PLC now owns 39,450 shares of the company’s stock worth $308,000 after acquiring an additional 30,093 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Sera Prognostics by 5.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 81,228 shares of the company’s stock worth $661,000 after acquiring an additional 4,115 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in Sera Prognostics by 10.6% during the 4th quarter. Rhumbline Advisers now owns 36,101 shares of the company’s stock worth $294,000 after acquiring an additional 3,468 shares in the last quarter. Hedge funds and other institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.